Long Form Content

Longer Form TLDR Biotech content that isn't the usual daily newsletter.

Long Form Content

CGT's Multi-Million Dollar Payer Problem - And a Potential Wall Street Fix

May 2, 2026

•

15 min read

CGT's Multi-Million Dollar Payer Problem - And a Potential Wall Street Fix

Why securitization might be the way towards greater CGT and advanced therapy access

Anis Fahandej-Sadi

Long Form Content

Biopunk & Community Labs: The Future For Biotech?

Apr 11, 2026

•

24 min read

Biopunk & Community Labs: The Future For Biotech?

Why the biotech of the future might be a lot smaller and a lot more nimble

Anis Fahandej-Sadi

Long Form Content

Dec 13, 2025

•

14 min read

The $4 Million Problem [Guest Post]

How a $25M startup is solving gene therapy's $4 million payment problem

Anis Fahandej-Sadi

Long Form Content

Building Scalable Biotech Industry Networks - The Biokeiretsu

Nov 29, 2025

•

12 min read

Building Scalable Biotech Industry Networks - The Biokeiretsu

Biotechnologies Are the Petrochemicals of the Electric Tech Stack

Anis Fahandej-Sadi

Long Form Content

Nov 22, 2025

•

12 min read

Why Biotech is Mortgaging Its Future

Inside the $3.5 Billion Biotech Royalty Financing Surge

Anis Fahandej-Sadi

Long Form Content

Beyond the Hype Cycle: Breakout Ventures' Nima Ronaghi on What Actually Drives Biotech Value

Sep 20, 2025

•

14 min read

Beyond the Hype Cycle: Breakout Ventures' Nima Ronaghi on What Actually Drives Biotech Value

Hot takes on value creation in biotech

Anis Fahandej-Sadi

Long Form Content

TLDR Biotech Big Three Saturday: American Biotech in Flux

Aug 30, 2025

•

9 min read

TLDR Biotech Big Three Saturday: American Biotech in Flux

Public health dismantling, Chinese asset deals continue, and domestic manufacturing only goes so far

Anis Fahandej-Sadi

Long Form Content

Moloch and Medicine: Why Good Intentions Built a Broken System, and Why CGT Might Fix It All (Sort Of)

Aug 23, 2025

•

21 min read

Moloch and Medicine: Why Good Intentions Built a Broken System, and Why CGT Might Fix It All (Sort Of)

Hot takes on current incentive structures

Anis Fahandej-Sadi

Long Form Content

The Biotech Funding Crisis: How Broken Models and Regulatory Chaos Are Reshaping an Industry

Aug 16, 2025

•

16 min read

The Biotech Funding Crisis: How Broken Models and Regulatory Chaos Are Reshaping an Industry

The biotech funding model needs a major overhaul

Anis Fahandej-Sadi

Long Form Content

Lowering CAR-T Costs: Paths to more affordable cell therapies

Jun 18, 2025

•

12 min read

Lowering CAR-T Costs: Paths to more affordable cell therapies

A long form piece by yours truly - originally published on Signals

Anis Fahandej-Sadi

Long Form Content

CGT's Multi-Million Dollar Payer Problem - And a Potential Wall Street Fix

Biopunk & Community Labs: The Future For Biotech?

The $4 Million Problem [Guest Post]

Building Scalable Biotech Industry Networks - The Biokeiretsu

Why Biotech is Mortgaging Its Future

Beyond the Hype Cycle: Breakout Ventures' Nima Ronaghi on What Actually Drives Biotech Value

TLDR Biotech Big Three Saturday: American Biotech in Flux

Moloch and Medicine: Why Good Intentions Built a Broken System, and Why CGT Might Fix It All (Sort Of)

The Biotech Funding Crisis: How Broken Models and Regulatory Chaos Are Reshaping an Industry

Lowering CAR-T Costs: Paths to more affordable cell therapies

TLDR Biotech

Home

FAQ

Media Partners